Industries Minister KT Rama Rao stated that Telangana contributed 40% of India’s Pharma production and was home to over 1,000 lifesciences companies and growing, adding that the state was the only region in the world with more than 200 FDA-approved pharmaceutical manufacturing sites that produced both innovator and generic medicines.
Speaking at the inaugural function of the BioAsia 2023 event, he stated that the State’s capability would be further strengthened with the establishment of Hyderabad Pharma City, the world’s largest and most sustainable integrated pharma park.
The Pharma City has the potential to attract $8 billion in investment, and several companies have already expressed an interest in establishing operations there.
“While we are continuing to build on our strengths in small molecules, we have also started to make a giant leap towards advanced therapeutic modalities,” the Minister said.
With key players such as Dr Reddy’s Laboratories, Biological E, Bharat Biotech, Shantha Biotech, Aurobindo, Hetero, Gland Pharma, and Virchow Biotech, Hyderabad has led biological production in the country. Telangana is also building Biopharma the Hub (B-hub), which is a first-of-its-kind Growth-Phase Center and Biopharma Scale-up Manufacturing facility in India.
In addition, investments were being made in the cell and gene therapy space, and an Institute of Curative Medicine would be established in Hyderabad with the goal of providing affordable development and commercialization of new age curative therapies, particularly cell and gene therapy, for diseases pertinent to India.
ALSO READ: Life sciences ecosystem worth Rs 20.5L crore to be targeted by Telangana: KTR
Hyderabad was also home to the largest number of Indian and multinational pharmaceutical research service organisations offering medicinal chemistry, discovery biology, pre-clinical, clinical, drug development and clinical trial product manufacturing. It was safe to say that a significant percentage of current and future NCE approvals originate in Hyderabad, Rama Rao said.
Hyderabad was becoming a preferred location for lifesciences-focused Global capability centres (GCCs). BMS and Sanofi announced new facilities in Hyderabad, joining the likes of Novartis, Bayer, Medtronic, Thermofisher, and Schrodinger. These GCCs provide global support to R&D, analytics, innovation, and engineering teams. Over the next five years, the State will position Hyderabad as a highend GCC destination for the world’s leading lifesciences companies, he added.
(This story has been sourced from a third-party syndicated feed, agencies. Raavi Media accepts no responsibility or liability for the text’s dependability, trustworthiness, reliability, and data. Raavi Media management/ythisnews.com reserves the sole right to alter, delete or remove (without notice) the content at its absolute discretion for any reason whatsoever.)
